Recently, the Prostate Cancer Prevention Trial enrolled 18 882 men aged > or = 55 years with a prostate-specific antigen level of < 3.0 ng/mL and normal digital rectal examination findings, and randomized them to Finasteride 5 mg daily or placebo [8]. This evidence concerns the gene KLK3 and prostate carcinoma.